5cgf

Publication Abstract from PubMed

Clinically applied proteasome inhibitors induce cell death by concomitant blockage of constitutive and immunoproteasomes. In contrast, selective immunoproteasome inhibition is less cytotoxic and has the potential to modulate chronic inflammation and autoimmune diseases. In this study, we rationally designed decarboxylated peptides that covalently target a non-catalytic cysteine of the immunoproteasome subunit beta5i with alpha-chloroacetamide-containing sidechains. The enhanced isoform specificity decreased cytotoxic effects and the compound suppressed the production of inflammatory cytokines. Structure-based optimization led to over 150-fold selectivity for subunit beta5i over beta5c. This new compound class provides a promising starting point for the development of selective immunoproteasome inhibitors as potential anti-inflammatory agents.

Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine.,Dubiella C, Baur R, Cui H, Huber EM, Groll M Angew Chem Int Ed Engl. 2015 Nov 13. doi: 10.1002/anie.201506631. PMID:26563572^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.